FJX1 and cancer: In this study, we designed 6 MHC class I (HLA-A2 restricted) and 2 MHC class II (HLA-DR restricted) FJX1-derived sequence specific peptides (9–20 amino acids) and evaluated in vitro, their potential to stimulate NPC patient’s immune response towards target cancer cell lines overexpressing FJX1.